Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Mitomycin-C 10mg Powder for Solution for Injection (Kyowa): Company led drug alert
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led drug recall, to be actioned, for certain batches of: Mitomycin-C Kyowa 10mg Powder for Solution for Injection. Date issued: 12th November 2018 CLDA number: (18) A/09 MDR number: MDR 06-11/18 Batch number: 6058517 The above batch is being recalled because an out of specification result...
FMD webinar now on-demand
Community pharmacy contractors can now access an online recording of PSNC’s recent webinar about the Falsified Medicines Directive (FMD). More than 1,000 people registered for yesterday’s webinar hosted by Alastair Buxton, PSNC’s Director of NHS Services. Alastair used the event to explain how the introduction of FMD will affect the day-to-day working of community pharmacy teams and what they...
PSNC October Meeting: summary for contractors now available
PSNC’s October meeting was held on the 9th and 10th of the month in Swindon, and key agenda items included: Analysis of the 2018/19 funding offer; Revision of PSNC’s service development proposals; The first meeting of PSNC’s Brexit Forum; and Consideration of the pilot to integrate pharmacy and medicines optimisation into new care models. Download...
Secretary of State advances the prevention agenda
The Secretary of State for Health and Social Care, Matt Hancock MP, has released a policy paper setting out the Government’s plan to put prevention at the centre of healthcare. The paper, Prevention is better than cure, sets out plans to diagnose cancer earlier, tackle obesity and use technology to predict illness, in a drive to...
Update to adrenaline 150 microgram auto-injector validation protocol – urgent action required by pharmacy teams
A revised interim protocol on dispensing adrenaline 150 microgram auto-injectors has been issued by the Department of Health and Social Care (DHSC). Stock levels are now sufficient to ensure that – with immediate effect – every patient that presents a prescription will be able to have access to at least two adrenaline auto-injectors that are either in date...
Change in the classification of certain glucosamine containing products
Glucosamine containing products (GCPs), marketed as food supplements, with dosage levels of base glucosamine at 1178mg/day or higher can no longer be sold or supplied by pharmacy teams as they are now considered unauthorised medicines. It is important to note that under Regulation 47 of the Human Medicines Regulations 2012 it is an offence to...
Quality Payments: DoS Profile Updater now available
The Directory of Services (DoS) Profile Updater, which community pharmacy contractors will need to use to meet the DoS quality criterion of the second Quality Payments Scheme 2018/19, is now available. Contractors who plan to claim for the DoS quality criterion at the February 2019 review point are required to edit or confirm the information about...
Identifying carers and care workers eligible for a flu vaccination
Carers and employed care workers who are aged 18 years or over are included in the group of patients eligible for an NHS flu vaccination under the national Flu Vaccination service. It is really important for carers and care workers to get vaccinated as if they were to catch flu and become ill, the welfare...
October 2018 Price Concessions/NCSO – FINAL update
Department of Health and Social Care (DHSC) has today (01/11/2018) set the FINAL price concessions for October 2018. The new additions to the October 2018 price concessions list are below: Drug Pack Size Price Concession Allopurinol 100mg tablets 28 £2.54 Allopurinol 300mg tablets 28 £5.83 Furosemide 40mg tablets 28 £2.49 Lamotrigine 100mg tablets 56 £20.76...
FMD: 100 days to go – sign up for our webinar
Community pharmacy contractors need to comply with the requirements of the Falsified Medicines Directive (FMD) in one hundred days’ time (9th February 2019). To mark this key date on the road to FMD implementation, PSNC has undertaken a full review of the content of the FMD Source website, with updated information, resources and new FAQs...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
EU expands label of GSK/Innoviva’s COPD inhaler
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
MSD’s Keytruda approved for liver cancer
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Priority review for AZ/MSD’s Lynparza in first-line maintenance setting
US regulators have accepted an application from AstraZeneca and MSD for use of Lynparza as maintenance treatment for patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer.
MPs order release of documents on negotiations for Vertex’ CF drugs
The UK House of Commons' Health and Social Care Committee has requested documents and evidence from Vertex Pharmaceuticals, NHS England and the National Institute for Health and Care Excellence (NICE) regarding ongoing and lengthy negotiations about NHS funding for the firm’s cystic fibrosis treatments.
NICE says no to expanding use of AZ/MSD's Lynparza
The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca/MSD's Lynparza to a wider patient population with ovarian cancer.
Lenvima backed for NHS use to treat liver cancer
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
Liverpool Uni leads EU kidney research project
Liverpool University is to coordinate a European research project that aims to develop new devices and methods for diagnosing and treating kidney disease.
Hikma, Vectura to develop generic rivals to GSK's Ellipta portfolio
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline's Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
Mallinckrodt’s Niemann-Pick Type C drug fails to hit trial target
UK-based Mallinckrodt has revealed that its experimental therapy for Niemann-Pick Type C failed to hit targets in a recently completed registration trial.
NICE nod for Jazz’ AML chemo
Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
New alliance strives to advance human-based drug evaluation
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool have announced plans to work together on the development of next generation human cell models to advance human based drug discovery.
Entries now underway - showcase your talent alongside the best in the industry
The PharmaTimes International Clinical Researcher of the Year 2019 has been designed to recognise and reward the talent of entrants from all parts of the globe in this ultimate test.
AZ sells respiratory trio to Covis
AstraZeneca has handed over rights to a trio of non-core assets to Covis Pharma, as it continues to shed parts of its portfolio.
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/